Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 34.46 is 69% above its 4-year average of 20.39, near the high end of its 4-year range (0.00–44.33).
As of the fiscal period ended Tuesday, June 30, 2026. 5.60% above its 12-month average of 32.64.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 34.46.
QUICK RATIO (ACID-TEST)
34.46
QUICK RATIO (ACID-TEST) AVG TTM
32.64
QUICK RATIO (ACID-TEST) AVG 3Y
25.25
QUICK RATIO (ACID-TEST) AVG 5Y
N/A
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+5.60%
CURRENT VS 3Y AVG
+36.48%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 871 covered companies
CURRENT VS SECTOR MEDIAN
+928.76%
vs the sector median at left
Mineralys Therapeutics, Inc.
Market Cap
$1.96B
Quick Ratio (Acid-Test)
34.46
TTM Avg
32.64
3Y Avg
25.25
5Y Avg
N/A
Market Cap
$1.98B
Quick Ratio (Acid-Test)
6.16
TTM Avg
5.39
3Y Avg
6.60
5Y Avg
7.52
Market Cap
$1.93B
Quick Ratio (Acid-Test)
6.04
TTM Avg
7.13
3Y Avg
7.06
5Y Avg
6.77
Market Cap
$1.92B
Quick Ratio (Acid-Test)
2.52
TTM Avg
2.21
3Y Avg
2.25
5Y Avg
2.64
Market Cap
$1.90B
Quick Ratio (Acid-Test)
9.79
TTM Avg
11.31
3Y Avg
11.94
5Y Avg
12.05
Market Cap
$2.03B
Quick Ratio (Acid-Test)
4.97
TTM Avg
4.46
3Y Avg
5.74
5Y Avg
7.97
Market Cap
$2.03B
Quick Ratio (Acid-Test)
3.41
TTM Avg
4.73
3Y Avg
4.98
5Y Avg
5.02
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | $1.96B | 34.46 | 32.64 | 25.25 | N/A |
| AxoGen, Inc. (AXGN)vs › | $1.96B | 5.04 | 2.74 | 2.74 | 3.55 |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.98B | 6.16 | 5.39 | 6.60 | 7.52 |
| Vir Biotechnology, Inc. (VIR)vs › | $1.93B | 6.04 | 7.13 | 7.06 | 6.77 |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.92B | 2.52 | 2.21 | 2.25 | 2.64 |
| Zymeworks Inc. (ZYME)vs › | $1.90B | 6.32 | 4.46 | 5.51 | 5.22 |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.90B | 9.79 | 11.31 | 11.94 | 12.05 |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.03B | 4.97 | 4.46 | 5.74 | 7.97 |
| UroGen Pharma Ltd. (URGN)vs › | $2.03B | 3.41 | 4.73 | 4.98 | 5.02 |
| Progyny, Inc. (PGNY)vs › | $2.03B | 2.14 | 2.76 | 2.92 | 2.79 |
Quick Ratio
34.46
Excludes inventory
Current Ratio
34.46
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 34.46 |
| 2026-03-31 | 44.33 |
| 2025-12-31 | 43.76 |
| 2025-09-30 | 25.50 |
| 2025-06-30 | 15.12 |
| 2025-03-31 | 26.48 |
| 2024-12-31 | 14.02 |
| 2024-09-30 | 8.55 |
| 2024-06-30 | 11.20 |
| 2024-03-31 | 18.06 |
| 2023-12-31 | 23.76 |
| 2023-09-30 | 19.59 |
| 2023-06-30 | 43.42 |
| 2023-03-31 | 26.07 |
| 2022-12-31 | 13.98 |
| 2022-09-30 | 16.88 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
| 2021-12-31 | 2.20 |
